Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 15 Neoplasm Metastasis 5 Ovarian Neoplasms 3 Endometrial Neoplasms 3 Uterine Cervical Neoplasms 2 Sarcoma 2 Recurrence 2 Neoplasms 2 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Lymphoma 2 Glioma 2 Carcinoma, Renal Cell 2 von Hippel-Lindau Disease 1 Xanthogranuloma, Juvenile 1 Wilms Tumor 1 Uterine Neoplasms 1 Urinary Bladder Neoplasms 1 Unilateral Breast Neoplasms 1 Thyroid Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Sarcoma, Ewing 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Osteosarcoma 1 Neuroectodermal Tumors, Primitive, Peripheral 1

Interventions

Fulvestrant 3 trastuzumab deruxtecan 2 Letrozole 2 Injections 2 AZD9833 2 toripalimab 1 ribociclib 1 palbociclib 1 exemestane 1 abemaciclib 1 Ritonavir 1 Paclitaxel 1 Lead 1 Itraconazole 1 Goserelin 1 Anastrozole 1 AZD5305 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Breast Cancer × palbociclib × 30 days × Clear all

NCT06380751 2026-05-15

EvoPAR-BR01

AstraZeneca

Phase 3 Recruiting

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡